Mibezet (Ezetimibe)

Ezetimibe, the active ingredient in Mibezet, is a cholesterol absorption inhibitor presented as an oral tablet for oral use. It lowers blood cholesterol levels and is indicated for patients with hypercholesterolemia, heterozygous familial hypercholesterolemia, and primary hyperlipidemia. It is marketed across the European Union and conforms to EU pharmaceutical standards for patients requiring lipid management.

GNH USA supplies Mibezet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global distribution.

Ezetimibe, marketed as Mibezet, is used to lower cholesterol by reducing intestinal absorption, and is indicated for several lipid disorders.

- Hypercholesterolemia: reduces LDL‑cholesterol levels, helping achieve target lipid goals in patients with elevated total cholesterol. - Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when combined with statin therapy in genetically predisposed individuals. - Primary hyperlipidemia: lowers total cholesterol and LDL‑cholesterol as part of a comprehensive lipid‑lowering regimen.

Ezetimibe is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Abdominal discomfort - Diarrhea - Fatigue - Headache - Joint pain - Nausea

Serious or Rare Side Effects: - Elevated liver enzymes - Myopathy or rhabdomyolysis (especially with statins) - Severe allergic reactions such as rash or angioedema - Acute pancreatitis - Hepatotoxicity

Before initiating Mibezet, clinicians should consider several precautionary measures to ensure safe use.

- Liver function monitoring: assess baseline transaminases and repeat periodically during therapy. - Lipid profile assessment: evaluate LDL‑cholesterol response after 4–12 weeks. - Gallbladder disease evaluation: use caution in patients with a history of gallstones. - Hepatic impairment: adjust therapy or avoid use in severe liver disease. - Drug combination caution: avoid concomitant use with strong CYP3A4 inhibitors without supervision. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Ezetimibe may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: increases ezetimibe plasma concentrations, raising risk of adverse effects. - Gemfibrozil: may enhance ezetimibe exposure and potential muscle toxicity. - Bile acid sequestrants (e.g., cholestyramine): bind ezetimibe in the gut, markedly reducing its absorption.

Moderate Interactions (Monitor Closely): - Statins (especially high‑intensity): combined use can increase risk of myopathy; monitor muscle symptoms and CK levels. - Warfarin: ezetimibe may affect INR; check coagulation parameters regularly. - Antifungal azoles (ketoconazole, itraconazole): may modestly increase ezetimibe levels; observe for side effects.